Ann: Cellmid Signs Antibody Humanisation Collabor, page-10

re: Ann: Cellmid Signs Antibody Humanisation ... willial

I agree that patience is required for big returns but also note that every milestone achieved thus far has (to varying extents) derisked the practical application of MK and in the case of the latest ann MDK antibodies.

I don't believe there is likely to be a "magic bullet" ann until such time as one of the core product lines is commercialised. My expectation is that the SP will (or rather should) increment progressively until one of the many irons in the fire delivers significant royalties.

Given the intergral role of MDK in celluar functions, and the fact that is a key naturally occuring enzyme (rather than a manufactured product with limited shelf life), investment risk (while tangible) is in IMHO low. That said, I don't have any scientific qualifications so don't rely on my uninformed views. We should each do our own research.

cheers